Y-Mabs Therapeutics Return on Equity

Y-Mabs Therapeutics posts a ROE of -25.4%. That is above the Healthcare sector average of -100.59%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near -100.59% is typical. Y-Mabs Therapeutics's -25.4% is higher that level. That is roughly 74.7% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Y-Mabs Therapeutics's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -25.4%; use YoY and peer views to separate noise from signal.

Context for YMAB's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -100.59%), and (3) consistency with growth and profitability. This page covers the first two; Y-Mabs Therapeutics's other metric pages and overview cover the third.

Judging Y-Mabs Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -25.4% here, then scan peer and history charts to see if the gap is persistent.